New Mexico Heart Institute Treats First Patient in the United States with the Ovation Alto™ Abdominal Stent Graft System
New Procedure Treats Abdominal Aortic Aneurysm
Albuquerque, NM – March 31, 2017 The New Mexico Heart Institute is proud to announce that Dr. Steve Henao, MD, FACS, FACC, Chief of Vascular Surgery at New Mexico Heart Institute, successfully performed the first Ovation Alto™ abdominal stent graft system in the United States on Thursday, March 30, 2017 at the state of the art Hybrid Endovascular Suite at the Heart Hospital of New Mexico at Lovelace Medical Center. This next generation device is used for the treatment of abdominal aortic aneurysm (AAA).
“The Ovation Alto system gives us new endovascular aneurysm repair options to treat more patients, including those with complex or challenging aortic structure,” said Dr. Henao. “This is a significant advancement for patients with an abdominal aortic aneurysm. We are incredibly proud to be the first center in the United States to conduct this procedure.”
This was the first implant of the device in the United States. The device is manufactured by the Endologix corporation and is the latest generation of low profile polymer based therapies for aneurysm treatment offered exclusively by the company. This device provides treatment options for more patients afflicted by AAA than ever before, who may not otherwise be candidates for minimally invasive therapy.
New Mexico Heart Institute is one of the leading cardiology teams in the Southwest with more than 28 staff surgeons and cardiologists, all of which are board certified. NMHI practices state-of-the-art medicine by employing the latest cardiovascular imaging and fully integrated interventional, cardiothoracic, and vascular surgical approaches. The Institute’s services, a number of which are conducted in conjunction with the Heart Hospital of New Mexico, located next door, address a full-range of preventive, diagnostic, treatment, surgical, and rehabilitation needs. In addition, NMHI’s Clinical Research Department is represented by a team of full-time research coordinators who are dedicated to carrying out the research component of our mission through heightened patient knowledge, the development of new therapies, and the innovation of new technologies.
